Bioadaptives Stock Performance
| BDPT Stock | USD 0.02 0 5.56% |
The firm shows a Beta (market volatility) of 2.76, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, BioAdaptives will likely underperform. BioAdaptives right now shows a risk of 16.55%. Please confirm BioAdaptives treynor ratio and the relationship between the semi variance and period momentum indicator , to decide if BioAdaptives will be following its price patterns.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days BioAdaptives has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, BioAdaptives is not utilizing all of its potentials. The recent stock price uproar, may contribute to short-horizon losses for the private investors. ...more
BioAdaptives |
BioAdaptives Relative Risk vs. Return Landscape
If you would invest 4.02 in BioAdaptives on November 9, 2025 and sell it today you would lose (2.12) from holding BioAdaptives or give up 52.74% of portfolio value over 90 days. BioAdaptives is currently generating 0.0867% in daily expected returns and assumes 16.5522% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than BioAdaptives, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BioAdaptives Target Price Odds to finish over Current Price
The tendency of BioAdaptives Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.02 | 90 days | 0.02 | about 82.11 |
Based on a normal probability distribution, the odds of BioAdaptives to move above the current price in 90 days from now is about 82.11 (This BioAdaptives probability density function shows the probability of BioAdaptives Pink Sheet to fall within a particular range of prices over 90 days) .
BioAdaptives Price Density |
| Price |
Predictive Modules for BioAdaptives
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as BioAdaptives. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.BioAdaptives Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. BioAdaptives is not an exception. The market had few large corrections towards the BioAdaptives' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold BioAdaptives, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of BioAdaptives within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.23 | |
β | Beta against Dow Jones | 2.76 | |
σ | Overall volatility | 0.01 | |
Ir | Information ratio | -0.0052 |
BioAdaptives Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of BioAdaptives for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for BioAdaptives can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| BioAdaptives had very high historical volatility over the last 90 days | |
| BioAdaptives has some characteristics of a very speculative penny stock | |
| BioAdaptives has a very high chance of going through financial distress in the upcoming years | |
| BioAdaptives currently holds 450.26 K in liabilities. BioAdaptives has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist BioAdaptives until it has trouble settling it off, either with new capital or with free cash flow. So, BioAdaptives' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BioAdaptives sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BioAdaptives to invest in growth at high rates of return. When we think about BioAdaptives' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 19.78 K. Net Loss for the year was (1.05 M) with profit before overhead, payroll, taxes, and interest of 10.11 K. | |
| BioAdaptives currently holds about 49.58 K in cash with (158.65 K) of positive cash flow from operations. |
BioAdaptives Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of BioAdaptives Pink Sheet often depends not only on the future outlook of the current and potential BioAdaptives' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. BioAdaptives' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 20.4 M | |
| Cash And Short Term Investments | 83.1 K |
BioAdaptives Fundamentals Growth
BioAdaptives Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of BioAdaptives, and BioAdaptives fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioAdaptives Pink Sheet performance.
| Return On Asset | -3.43 | |||
| Operating Margin | (33.58) % | |||
| Current Valuation | 544.74 K | |||
| Shares Outstanding | 160.49 M | |||
| Price To Earning | (14.28) X | |||
| Price To Sales | 7.53 X | |||
| Revenue | 19.78 K | |||
| EBITDA | (643.76 K) | |||
| Cash And Equivalents | 49.58 K | |||
| Total Debt | 450.26 K | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (158.65 K) | |||
| Earnings Per Share | (0.02) X | |||
| Total Asset | 148.59 K | |||
| Retained Earnings | (2.96 M) | |||
| Current Asset | 156 K | |||
| Current Liabilities | 316 K | |||
About BioAdaptives Performance
Assessing BioAdaptives' fundamental ratios provides investors with valuable insights into BioAdaptives' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the BioAdaptives is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
BioAdaptives, Inc. markets and distributes natural plant and algal-based products for humans and animals. BioAdaptives, Inc. was incorporated in 2013 and is based in Las Vegas, Nevada. Bioadaptives operates under Packaged Foods classification in the United States and is traded on OTC Exchange. It employs 3 people.Things to note about BioAdaptives performance evaluation
Checking the ongoing alerts about BioAdaptives for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for BioAdaptives help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioAdaptives had very high historical volatility over the last 90 days | |
| BioAdaptives has some characteristics of a very speculative penny stock | |
| BioAdaptives has a very high chance of going through financial distress in the upcoming years | |
| BioAdaptives currently holds 450.26 K in liabilities. BioAdaptives has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist BioAdaptives until it has trouble settling it off, either with new capital or with free cash flow. So, BioAdaptives' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BioAdaptives sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BioAdaptives to invest in growth at high rates of return. When we think about BioAdaptives' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 19.78 K. Net Loss for the year was (1.05 M) with profit before overhead, payroll, taxes, and interest of 10.11 K. | |
| BioAdaptives currently holds about 49.58 K in cash with (158.65 K) of positive cash flow from operations. |
- Analyzing BioAdaptives' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioAdaptives' stock is overvalued or undervalued compared to its peers.
- Examining BioAdaptives' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioAdaptives' management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioAdaptives' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioAdaptives' pink sheet. These opinions can provide insight into BioAdaptives' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for BioAdaptives Pink Sheet Analysis
When running BioAdaptives' price analysis, check to measure BioAdaptives' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAdaptives is operating at the current time. Most of BioAdaptives' value examination focuses on studying past and present price action to predict the probability of BioAdaptives' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAdaptives' price. Additionally, you may evaluate how the addition of BioAdaptives to your portfolios can decrease your overall portfolio volatility.